Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 ...

Cantor Fitzgerald downgraded Amgen (AMGN) to Neutral from Overweight.Stay Ahead of the Market: Discover outperforming stocks and invest ...

As previously reported, Cantor Fitzgerald downgraded Amgen (AMGN) to Neutral from Overweight with a price target of $305, down from $340, as ...

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

the first such decision to support the controversial attempts by some states to control their prescription drug spending. The case had been filed last year by Amgen after the state Prescription ...

It was backed initially by several million US dollars in venture capital funding and its first CEO, George Rathamann, was a former Vice President at Abbott. The Californian location put Amgen ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Amgen expects to wrap up its FDA submission for Uplizna in gMG in the first half of this year. The quick expansion push for Uplizna comes after the drug was first approved in 2020 for ...

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

The FDA approved Amgen’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the “first and only treatment” approved for this indication, according to the ...

Amgen When Dr. David Reese, Amgen’s first chief technology officer, set about hiring a head of artificial intelligence last year, he looked at people who’d worked in consumer products, finance ...